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Purpose: Fragile X-associated tremor/ataxia syndrome (FXTAS) was originally defined as
tremor, ataxia, cognitive decline, and parkinsonism in individuals who carry between 55
and 200 CGG repeats in the promoter region of the fragile X mental retardation 1 (FMR1)
gene. This paper describes a series of patients who meet the definition of FXTAS who
presented for care between 2009 and 2014.
Methods/Results: Retrospective chart review of patients seen in the FXTAS clinic at Rush
University in Chicago.
Conclusions: Patients with FXTAS may present with a progressive supranuclear palsy-like
phenotype and other eye movement abnormalities are common in these patients as well.
Rapid worsening of gait abnormalities in FXTAS may be due to a secondary spinal issue
and should be aggressively treated to regain function. Finally, the FXTAS Rating Scale
score does not reliably inform the certainty of diagnosis or CGG repeat size in these
patients.
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INTRODUCTION
Fragile X-associated tremor/ataxia syndrome (FXTAS) is caused
by expansion in the trinucleotide CGG repeat in the pro-
moter region of the fragile X mental retardation 1 (FMR1) gene.
Classical clinical manifestations include kinetic tremor, cerebellar
ataxia, cognitive decline, psychiatric problems, and parkinson-
ism (Jacquemont et al., 2003, 2004; Berry-Kravis et al., 2007a).
Other features include peripheral neuropathy (Berry-Kravis et al.,
2007b), impotence and autonomic dysfunction (including bowel
and/or bladder dysfunction and erectile dysfunction) (Louis et al.,
2006; Leehey, 2009). Cognitive decline manifests as a frontal
subcortical dementia, with memory loss and executive function
deficits and often lack of insight into these deficits (Grigsby et al.,
2007). Psychiatric effects of FXTAS include anxiety, mood lability,
apathy, and social phobias (Bourgeois et al., 2006). It is most fre-
quently seen in individuals over the age of fifty who carry between
55 and 200 CGG repeats, also known as the “premutation.” Fragile
X syndrome (FXS), the most common inherited form of intel-
lectual disability, results from the presence of more than 200
CGG repeats and is characterized by intellectual disability, autism,
attention deficit disorder, and often seizures.
FXTAS has distinct features on magnetic resonance imaging
(MRI), including severe generalized atrophy, cerebellar atrophy,
and sub-cortical and/or ponto-cerebellar white matter lesions
(Greco et al., 2006). About 60% of males with FXTAS have what
is known as the “MCP sign,” or T2 hyperintensity in the mid-
dle cerebellar peduncle (Adams et al., 2007). Hyperintensities in
the splenium of the corpus callosum on MRI may also be seen
(Apartis et al., 2012).
The estimated prevalence of the FMR1 premutation is between
1/151 and 1/209 in women and 1/430—1/468 in men (Seltzer
et al., 2012; Tassone et al., 2012b). Since its initial description,
more women with FXTAS are being identified. Some medical
comorbidities may be more common in premutation carrier
women, including thyroid disease, hypertension, seizures, and
fibromyalgia (Coffey et al., 2008; Leehey et al., 2011). The pur-
pose of this project is to demonstrate the heterogeneity in patients
presenting for clinical care of FXTAS.
BACKGROUND
Thirty patients with FXTAS were seen between 2009 and 2014
for clinical care in the FXTAS Clinic. Nineteen cases with
complete clinical information were summarized for this study.
Their clinical characteristics are described in Table 1. FXTAS
Motor Rating Scale scores are listed in the table and encom-
pass the major movement disorder signs seen in FXTAS: tremor,
ataxia, and parkinsonism. This rating scale was developed in
2008. It is a combination of the Clinical Rating Scale for
Tremor (CRST), the International Cooperative Ataxia Rating
Scale (ICARS) and the Unified Parkinson’s Disease Rating Scale
(UPDRS). It also includes a tandem test for cerebellar gait ataxia
(Leehey et al., 2008). Four cases illustrative of the series have been
included.
CASE 7
A 70 year-old man with history of myeloproliferative disorder
presented with 3 years of balance problems and falls. He felt
he was veering to one side when he was walking. He denied
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tremors and memory problems. On examination, he scored a
24/30 on the FolsteinMiniMental Status Exam (MMSE) (Folstein
et al., 1975) with deficits in attention, recent memory, and exec-
utive function. He had dysmetric saccades. Sensory exam was
notable for inconsistent vibratory loss in the feet and temper-
ature loss in all extremities. He had mildly increased tone in
both arms and mild kinetic tremor when drawing spirals. He had
mild bradykinesia bilaterally. He had no evidence of dysmetria.
His gait was wide based and ataxic. He was profoundly unsta-
ble when standing or walking, with almost immediate falling.
He refused to use a walking aid. Brain MRI showed cerebral
volume loss, hyperintensity in the cerebral peduncles, and the
MCP sign. He was admitted due to a lack of safety with his
balance and had a three-week rehabilitation stay. There he devel-
oped a sudden onset bilateral leg weakness. Workup revealed
a large soft tissue mass in his spinal cord extending from T1
to T9 causing significant cord compression. It was resected and
pathology was consistent with extramedullary hematopoeisis.
He then underwent successful radiation therapy. After contin-
ued rehabilitation, he was able to regain prior function and
is currently walking with a walker. His family history was
remarkable for a sister and multiple grandchildren with FXS.
His mother had fragile X-associated primary ovarian insuffi-
ciency (FXPOI). His FMR1 CGG repeat size was 99. He met
criteria for definite FXTAS, with tremor, ataxia, and the MCP
sign on MRI.
CASE 9
A 75 year-old woman presented with a one-year history of balance
problems, which she described as wobbling when she walked. She
had fallen once. She denied tremors, but had decreased hear-
ing in both ears, urinary frequency, and fatigue. Her past history
was remarkable for diabetes, end stage renal disease, and vitiligo.
On examination, she had normal cognition, saccadic pursuits,
and transient endgaze nystagmus. She had increased tone in the
right armwithout cogwheel rigidity, anterocollis, andmild kinetic
tremor with handwriting. Reflexes were absent in the extremities
and sensation was decreased to temperature. Dysdiadochokinesia
was present in the left hand and bradykinesia in the left leg.
She was unable to stand or walk in tandem and got off bal-
ance when she turned quickly. There was no retropulsion on
the pull test. Brain MRI showed cerebral and cerebellar vol-
ume loss with white matter hyperintensities in the periventricular
region.
The following year, she had a fall and had surgery for a
“pinched nerve” in the neck. She began to have visual hallucina-
tions in the hospital and was started on haloperidol. Her exam-
ination had dramatically worsened: she was wheelchair bound
and was no longer able to walk unless she had assistance. Her
MMSE was 18/30. She then developed delusions and depres-
sion. Quetiapine and venlafaxine were added and haloperidol
discontinued. She received aggressive inpatient and outpatient
rehabilitation over the next 3 months and regained the ability to
walk using a walker. Her FMR1 CGG repeat sizes were 90 and 29.
She had a daughter, two nephews, and one niece with FXS. She
met criteria for definite FXTAS, with tremor, ataxia, and white
matter disease on MRI.
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CASE 12
A 72 year-old woman presented with progressive difficulty walk-
ing since 1998. She initially attributed this difficulty to pain in
her feet, and was subsequently diagnosed with plantar fasciitis.
By 2000–2001, she developed postural dizziness and soon devel-
oped a slow, festinating gait with decreased arm swing as well
as fatigue, cognitive slowing, and trouble sleeping. By 2009 she
was wheelchair bound. MRI of her brain revealed white mat-
ter lesions in the pons and periventricular regions. Testing for
autoimmune disorders and spinocereballar ataxias (SCA) was
negative. She failed treatment with amantadine and was started
on carbidopa/levodopa 25–100mg twice daily and her walking
improved.
On examination at age 75, her MMSE was 25/30, with deficits
in executive function, recent memory and verbal fluency. She
had apraxia in her left hand and foot, a positive glabellar reflex,
and trouble mimicking on the left side. She had absent vertical
optokinetic nystagmus, slowed vertical saccades, and square wave
jerks. She was bradykinetic and had resting tremor in both arms.
Her gait was remarkable for short stride length, frequent freez-
ing, difficulty with tandem gait and impaired postural reflexes.
Her carbidopa-levodopa was weaned due to persistent nausea.
Donepezil 10mg daily was started given her cognitive decline. She
continued frequent physical therapy at home, but her symptoms
continued to progress. She is a FMR1 premutation carrier with 88
FMR1CGG repeats. Her son has intellectual disability but has not
been tested for FXS. Her father had severe tremor and ataxia. Her
sister has fragile X-associated premature ovarian insufficiency
(FXPOI). She has a male cousin with FXTAS and three female
cousins who are also premutation carriers. Based on her MRI as
well as ataxia and tremor, she met criteria for definite FXTAS.
CASE 18
An 80 year-old man presented with a three-year history of wors-
ening falls. He had developed shuffling gait, a soft voice, was
choking on food, and had a masked facial expression. He denied
tremor. He had been diagnosed by a prior neurologist with
Parkinson disease and started on 3.5 tablets of 25–100mg car-
bidopa/levodopa. By report, his symptoms did not improve. On
examination at the age of 80, his MMSE was 28/30. He had
a positive glabellar reflex and negative applause sign. He had
impaired vertical gaze, impaired vertical optokinetic nystagmus,
and slowed saccades. He had symmetrically increased tone in both
upper extremities and bradykinesia in all four extremities. He had
left sided shoulder elevation with a mild rightward head turn. He
had mild rest tremor in the left hand and mild kinetic tremor
when drawing spirals. There was no evidence of dysmetria. He
had a positive pull test, was unable to perform tandem gait, and
took multiple steps to turn. His steps were slow and short. He was
unable to have a MRI, but brain CT showed ventriculomegaly. He
was started on 5mg twice daily of memantine given complaints
of poor memory, however this was subsequently discontinued
as it proved ineffective. His falls initially decreased in frequency
after physical therapy. Within 8 months of presentation, he was
unable to walk on his own, even with a walker. He had a retrial
of carbidopa/levodopa 25–100mg three pills daily. His bradyki-
nesia improved mildly, but he began experiencing delusions and
hallucinations. The psychosis improved and entacapone 200mg
three times daily was added. The patients’ family felt the enta-
capone helped the speech problems, but not the other motor
features. He was a FMR1 premutation carrier with 68 FMR1
CGG repeats. His grandson had FXS. He met criteria for probable
FXTAS given his tremor and ataxia, but lack of a MRI.
DISCUSSION
These cases have some similarities and differences to previously
reported FXTAS phenotypes. The majority of the patients have
a mixed movement disorder, with signs of tremor, ataxia, and
parkinsonism. In addition, neuropathic findings and neuropsy-
chiatric issues are common, with many having cognitive deficits
on presentation. Our cases were found primarily in families with
known fragile X-associated disorders. All of these features have
been previously described.
Case 12 describes a woman with a strong family history of
FMR1 mutation associated diseases. Her course began with gait
difficulty and evolved to include eye movement abnormalities
consistent with progressive supranuclear palsy (PSP). In Case 18,
the patient’s history of falls at symptom onset, absence of response
to carbidopa/levodopa, and upgaze palsy is most consistent
diagnostically with PSP. This is a neurodegenerative movement
disorder characterized by early falls, supranuclear ophthalmople-
gia (particularly of vertical eye movements), parkinsonism, and
later cognitive decline. In addition, several of the other cases in
Table 1 had eye findings often seen in PSP, including decreased
optokinetic nystagmus, especially in the vertical direction, slowed
vertical saccades, and the presence of square wave jerks (Litvan
et al., 1996). Case 2 demonstrated lack of vertical optokinetic
nystagmus. Cases 13 and 17 demonstrated saccades which were
hypometric and slow, respectively. A PSP phenotype has not been
reported in FXTAS in the past. Schrag et al. (2006) estimated
the prevalence of PSP in the general population at about 6 per
100,000. The prevalence of FXTAS has been reported at 1/4000
in men over 55 (Hall and Jacquemont, 2010). Given the rarity of
these two disorders, it may be more than coincidence that five
individuals in our series had a PSP-like phenotype.
It is unclear in our patients whether the PSP-like phenotype
is a variation of FXTAS, whether this represents the presence of
PSP in FMR1 premutation carriers, or whether these patients
have two neurodegenerative disorders. Most likely, the pathways
involved with the classic eye findings and falls in PSP located
in the brainstem are also involved in FXTAS, resulting in simi-
lar phenotypic presentations. However, previous case series have
shown that FMR1 premutation carriers may have dual pathology
on autopsy, specifically in cases of FXTAS and Alzheimer disease,
and suggest that they may be synergistic in creating a worse neu-
rological phenotype (Tassone et al., 2012a). Autopsy on our cases
will help to clarify this issue. The typical neuropathology associ-
ated with FXTAS is enlarged, inclusion-bearing astrocytes in the
cerebral white matter and intra-nuclear inclusions in both the
brain and spinal cord (Greco et al., 2006). This differs from the
neuropathological findings seen in PSP, in particular neurofibril-
lary tangles and/or neutrophil threads in the striatum, substantia
nigra, occulomotor complex, peri-aqueductal gray, superior col-
liculi, basis pontis, dentate nucleus, and prefrontal cortex (Litvan,
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2005). Other abnormal and non-specific eye movement abnor-
malities were common in our cases. These are not thought to
be part of FXTAS, but this topic needs to be studied further to
determine if these are unique features of FXTAS that could aid in
clinical diagnosis.
Cases 7 and 9 illustrate a more rapid progression of neurolog-
ical signs commonly seen in FXTAS due to other spinal issues.
The quicker deterioration might be due to a cumulative effect
of a spinal cord problems and long tract dysfunction related to
the premutation, which lead to a double hit of pathology in
the crossing cerebellar fibers in the middle cerebellar peduncle
(from the underlying FXTAS) and the afferent spinocerebellar
fibers that travel up the spinal cord. In both cases, rapid diagnosis
and aggressive rehabilitation were sufficient to improve the out-
come of the acute worsening of the gait disorder in these patients.
Clinicians should be alerted to monitor abrupt changes in the
gait symptoms in FXTAS patients as this may be improved back
to baseline if an underlying cause is found. It is also important
to note that, like our patient, many FXTAS patients benefit from
physical therapy, and thus it should be included as an integral part
of their treatment.
Interestingly, the FXTAS Rating Scale scores did not appear
to coincide with the number of CGG repeats or the certainty
of diagnosis. Patients with “definite” FXTAS had FXTAS Rating
Scale scores as low as 30 and as high as 75, with a range of
CGG repeat between 74 and 124. Patients whose diagnosis was
“probable” FXTAS had FXTAS Rating Scale Scores between 17
and 81, with repeat sizes that ranged from 55 to 150. “Possible”
FXTAS patients had rating scales that ranged from 7 to 41,
with CGG repeat sizes ranging from 85 to 120. The discrep-
ancy between FXTAS rating scale and certainty of diagnosis may
be explained by the fact that the diagnostic criteria of FXTAS
require radiological signs on MRI for a definite FXTAS diagno-
sis and some of our patients were unable to have MRI imaging.
This would have lowered the certainty of diagnosis in those
cases.
A final observation seen is that the women who meet crite-
ria for FXTAS had milder movement disorders than the men.
Several published case series have suggested that the pheno-
type may be milder in women due to X-inactivation and the
presence of a normal FMR1 allele. With the exception of one
female case in Table 1, this was also the case in our group of
patients.
CONCLUDING REMARKS
This case series illustrates some new observations in patients with
FXTAS. It also confirms the heterogeneity of the FXTAS pheno-
type which has previously been described, even in cases when the
diagnosis is considered “definite.” The phenotype may include a
PSP-like presentation. Rapid progression of the gait ataxia may be
secondary to another spinal cord issue and should be investigated.
In addition, the FXTAS Rating Scale score may not be informative
regarding diagnosis. Additional studies in FXTAS cohorts, includ-
ing autopsy, are needed to confirm these findings. The clinical
heterogeneity of this disorder has implications for clinical trials
in FXTAS, making outcomes based on clinical phenotypes alone
less practical.
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